Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoantigen DC Vaccine + PD-1 + Radiotherapy in Advanced NSCLC
NCT06751849Phase 2Recruiting
- Sponsor
- First Affiliated Hospital of Nanchang University
- Start
- Mar 2024
- Primary completion
- Mar 2026
- Modality
- Whole Cell Cancer Vaccines, Dendritic Cell Vaccines
- Countries
- 1
01
Overview
A Phase 2 trial of Neoantigen-loaded DC vaccine in non-small cell lung cancer (NSCLC), sponsored by First Affiliated Hospital of Nanchang University. Started Mar 2024; status: recruiting.
02
Drugs
Neoantigen-loaded DC vaccine
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06751849.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06751849.